Type 2 diabetes is characterised by a progressive deterioration of the prandial insulin response, in a situation of continuing insulin resistance. Early phase insulin release is attenuated and delayed and there is a consequent failure to suppress glucagon secretion and curtail hepatic glucose production and gluconeogenesis. Postprandial plasma glucose concentration rises to pathological levels and fails to return to normal before the patient consumes their next meal, creating a problem of continuous daytime hyperglycaemia. Although late insulin secretion is preserved it does not rectify the hyperglycaemia. The pathology of excessive prandial glucose excursions and continual daytime hyperglycaemia can be normalised, at least in part, if early-phase insulin availability is restored through pharmacologic intervention. Initially, the feasibility of this approach was demonstrated experimentally with the use of carefully controlled insulin infusions or insulin analogue injections. More recently, the availability of the rapid or early augmentor of insulin secretion Ð repaglinide Ð provides a means for restoring prandial glucose regulation with oral therapy. Placebo-controlled and oral hypoglycaemic agent (OHA) comparative studies of repaglinide have established its antidiabetic ef®cacy and¯exible mealtimeadosing studies have con®rmed the importance of the prandial approach to treatment. Prandial glucose regulation with repaglinide has also been demonstrated to provide synergies when used as combination therapy with insulin sensitising agents. As a strategy, prandial glucose regulation has a number of theoretical advantages over the use of ®xed doses of conventional insulin secretagogues, and these have been borne out in clinical trials. As well as offering a more¯exible approach to treatment, prandial repaglinide is associated with a reduced risk of severe hypoglycaemia.
Introductioǹ
Prandial glucose regulation' is the term that has come to be applied to a treatment strategy for Type 2 diabetes that seeks to increase the clearance of plasma glucose after each meal (and hence restore physiological plasma glucose promptly) through the use of a fast-acting insulin secretagogue. It is analogous to the basal-bolus strategy for administration of exogenous insulin, now common practice in the treatment of Type 1 diabetes. 1 The ®rst oral prandial glucose regulator is the carbamoylmethyl benzoic acid derivative, repaglinide. In contrast to the use of ®xed-dose, long-acting sulphonylureas, prandial glucose regulation with repaglinide does not require patients to conform to a strict mealtime regimen nor take regular snacks to prevent hypoglycaemia. These behaviours are required of sulphonylurea-treated patients because the insulinotropic action of these agents is continuous with recommended dose regimens and is not fully glucose-regulated. 2 Prandial glucose regulation is therefore appealing in that it has the potential to offer patients a greater freedom in their eating habits as well as a reduced risk of major hypoglycaemia. However, therapeutic success with prandial glucose regulation, in terms of improving overall metabolic control, also requires that basal or fasting' hyperglycaemia be attenuated potentially by correcting abnormalities in the regulation of glucose in the prandial setting. This article reviews the evidence for the therapeutic potency of prandial glucose regulation with repaglinide in experimental and clinical practice.
The pathophysiological rationale for prandial glucose regulation Type 2 diabetes mellitus is characterised by at least two major metabolic derangements, including de®cits in both insulin secretion and insulin action. There continues to be much debate about the primacy and relative contribution of insulin resistance and impaired beta-cell function in the aetiology of the disease, but the evidence increasingly implicates impaired prandial insulin release as an important cause of hyperglycaemia in both the postprandial and ultimately in the fasting state.
In the normal state, insulin secretion can be divided into a ®rst and second phase. The ®rst or early-phase of secretion reaches a peak at about 10 min after betacell stimulation. 3, 4 This is followed by a more prolonged second or late phase of insulin secretion that persists for the period of hyperglycaemia. The net effect is to limit the extent to which blood glucose concentration increases in the postprandial period. In fact, in health, mean blood glucose following a meal is limited to peak concentrations of less than 7.0 mmolal, and concentrations greater than 5.5 mmolal are rarely, if ever, seen for more than 30 min. 1, 5 Furthermore, the early-phase insulin response to a meal may precede the rise in plasma glucose, presumably through the action of incretins and neurological stimuli. These observations imply that it is of physiological importance to limit glucose excursions, with high plasma glucose concentrations thereby avoided. 1 In Type 2 diabetes, and in impaired glucose tolerance (IGT), the early-phase of the prandial insulin response is delayed and blunted. 3,6 ± 11 Cross-sectional studies suggest that this derangement is progressive and may be fundamental in disease aetiology. For example, when newly-diagnosed, therapy-naõ Ève patients were strati®ed by fasting glycaemia at time of diagnosis, they were found to have impairments of the prandial insulin response (with corresponding postprandial glucose excursions) that correlated with their fasting blood glucose levels. 12 Measurement of prandial insulin pro®les showed that total insulin release measured over 4 h from commencing a meal was relatively increased in patients with fasting plasma glucose concentrations less than 9 mmolal. However, in patients with higher concentrations of fasting plasma glucose, total insulin release declined progressively to subnormal levels. These ®ndings imply that in developing Type 2 diabetes, there is a progressive delay and attenuation of the prandial insulin response that is initially compensated for by an increase in late-phase insulin output. However, this relative increase in insulin is only apparent from 2 h after eating a meal, and cannot effectively restrain the postprandial rise in plasma glucose. Eventually, the compensatory increase in late insulin output itself appears to decline Ð a supposition that has been con®rmed in longitudinal studies of ethnic cohorts with high incidences of Type 2 diabetes. 13, 14 An important cause of the excessive prandial blood glucose elevations characteristic of Type 2 diabetes appears to be a failure to suppress endogenous hepatic glucose production at this time. This is in addition to a failure to clear dietary glucose owing to defective insulin secretion in the face of peripheral insulin resistance. The importance of hepatic glucose production was illustrated by Mitrakou and colleagues in a metabolic study of subjects with and without Type 2 diabetes, in which a radiolabelled oral glucose load was used to assess glucose dynamics. 15 Subjects with Type 2 diabetes were characterised in the basal and post glucose challenge state by a signi®cantly greater output of endogenous glucose than healthy controls (13.7 g vs 6.8 g, P`0.01). In relative terms, the subjects with Type 2 diabetes had a lower glucose disposal rate given their higher plasma glucose concentrations, so`insulin effectiveness' was impaired. Mitrakou et al also highlighted the potential role of glucagon in the failure to suppress endogenous glucose production. The glucose excursions in subjects with Type 2 diabetes were associated, not only with a delayed and blunted insulin response, but also with a Figure 1 Plasma responses to an oral glucose load in healthy subjects and in subjects with Type 2 diabetes. Type 2 diabetes is characterised by a delayed and blunted insulin response and a failure to suppress glucagon secretion, with a subsequent supraphysiological glucose excursion. Adapted from reference 15. failure to suppress glucagon secretion (Figure 1) , most likely as a result of a reduced insulin paracrine action: similar ®ndings were subsequently made in subjects with IGT. 7, 15 Since glucagon is an important promotor of hepatic gluconeogenesis, 15 a reduced ratio of insulin : glucagon early in the prandial setting may be an important pathophysiological defect participating in the postprandial hyperglycaemia of Type 2 diabetes.
The pharmacological rationale for prandial glucose regulation Given the observations described above, it would seem that treatment strategies aimed at normalising the prandial insulin pro®le may in part represent an important approach to restoring normoglycaemia in Type 2 diabetes. The goal would be to provide suf®cient insulin early enough in the prandial setting to inhibit glucagon secretion and to suppress endogenous hepatic glucose production. Insulin availability should also be of suf®cient magnitude and duration to ensure adequate disposal of the prandial load. Continued suppression of counter-regulatory hormone excess may then lead to improvements in fasting hyperglycaemia.
Markovic et al showed that a 1.8 U prandial insulin infusion given for 30 min from the commencement of a meal had a greater glycaemic bene®t in relation to insulin exposure than a 3.6 U infusion given over 60 min. 16 More recently, Bruttomesso et al gave injections of either regular human insulin or a rapidly absorbed insulin analogue prior to a radiolabelled 50 g oral glucose load in patients with Type 2 diabetes. 17 Although the total areas under the plasma insulin concentration curves were similar with both insulins, the analogue was associated with a higher T max and C max , followed by a more rapid decline. This was associated with a reduced plasma glucose excursion and a reduction in the area under the plasma glucose curve of 46%. Kinetic analyses suggested that the improved glucose tolerance was due to more complete suppression of endogenous glucose output. Importantly, the analogue was also associated with lower plasma glucose levels throughout a 5 h assessment period despite plasma insulin levels being lower from the second hour. These studies suggest that interventions that increase insulin availability early in the prandial setting can in¯uence plasma glucose levels late in the postprandial period more effectively than late increases of insulin. However, it is important that insulin availability is of a suf®cient duration to achieve ef®cient disposal of the prandial glucose, as well as suppression of endogenous glucose output. In a study of preprandial intranasal insulin in Type 2 diabetes, the plasma peak of insulin occurred so quickly and over such a short duration that there was no improvement in the postprandial blood glucose excursion. 18 Nevertheless, the important conclusion to be drawn from pharmacological studies that have examined modulation of the prandial insulin response is that the timing of insulin availability is perhaps more important than total insulin exposure. Interventions where insulin is increased early enough in the prandial setting to effectively curtail the postprandial glucose excursion are associated with better glycaemic control several hours later Ð even if insulin levels are lower at this time-point than with comparative treatment regimens. This implies that the likelihood of therapeutic ef®cacy and hypoglycaemic risk are independent variables with insulinotropic therapies.
Prandial glucose regulation with repaglinide: the clinical evidence
Repaglinide is absorbed rapidly, reaching maximum plasma concentrations 50 min after oral dosing, with a terminal elimination half-life of 32 min. 19 It is extensively metabolised in the liver by the cytochrome P-450 system, and its inactive metabolites are excreted in bile. 20 Thus, repaglinide does not accumulate in patients with Type 2 diabetes and mild-to-moderate renal dysfunction, in whom the rate of elimination and area under the plasma concentration curve have been shown to be unchanged relative to patients with normal renal function. 21 These kinetic properties are, theoretically, ideal for prandial glucose regulation in patients with Type 2 diabetes. In contrast to glibenclamide, repaglinide has been shown in vitro to have an insulin secretagogue action that is more completely dependent on the presence of glucose. 22, 23 Thus, repaglinide enhances glucose-mediated insulin release, another property suited to its employment in prandial glucose regulation. Of greatest importance however, is the ®nding that repaglinide, but not glibenclamide, accelerates early insulin release, clearly establishing the potential for prandial regulation with repaglinide.
The antidiabetic ef®cacy of repaglinide is now established from a number of placebo-controlled and comparative trials. Prandial repaglinide has been shown to improve all parameters of glycaemic control that have been assessed, including not only postprandial blood glucose concentrations but also HbA 1c and fasting blood glucose concentrations 24 ± 26 (also discussed by Landgraf et al 27 in this publication). For example, in a recent, prospective, double-blind, placebo-controlled study, Jovanovic et al randomised 286 patients with Type 2 diabetes to receive either 1 or 4 mg of repaglinide prior to each of three main meals (breakfast, lunch and dinner), while a further 75 patients were randomised to receive placebo at these times. 26 At endpoint, fasting plasma glucose had decreased by 66 mgadl (3.7 mmolal) and 68 mgadl (3.8 mmolal) in patients receiving 1 and 4 mg doses respectively, in comparison to placebo (both P`0.001). In terms of HbA 1c , there were decreases of 1.8 and 1.9 percentage points in patients receiving 1 and 4 mg doses respectively, relative to placebo (P`0.001). Subgroup analysis showed the improvement in fasting plasma glucose and HbA 1c to be greatest among therapy-naõ Ève patients, in whom there was also more evidence of a dose-response relationship (Figure 2) . The curves of HbA 1c reductions vs time also suggested that the antidiabetic ef®cacy of repaglinide was maximal at 10 weeks and maintained thereafter. Another placebo-controlled study randomised 99 patients who had already been receiving antidiabetic medications after a 2-week washout period. 25 After 18 weeks of treatment, repaglinide was associated with a decrease in HbA 1c from 8.5% to 7.8%, while HbA 1c increased from 8.1% to 9.3% in recipients of placebo (a treatment effect of À1.9% HbA 1c , between-group difference, P`0.0001).
Surprisingly, a primary effect on prandial glucose regulation was accompanied by substantial improvements in fasting glucose and HbA 1c equivalent to that of glibenclamide 28 ± 30 and superior to glipizide, 31 yet to incur a 60% lower risk of severe hypoglycaemia (P`0.03). 32 A potential advantage of prandial glucose regulation is that patients can adopt¯exible meal patterns on a day-by-day basis, both in terms of the number of main meals and the times at which they are eaten. Two studies have con®rmed the ef®cacy of repaglinide when used in these circumstances. A 16-week, placebo-controlled study of 408 patients naõ Ève to antidiabetic pharmacotherapy and poorly controlled by diet showed repaglinide to improve glycaemic control regardless of the meal pattern followed by the patient. 33 In this study, repaglinide was associated with a signi®cant improvement in HbA 1c from 7.8% at baseline to 6.6% at endpoint (P`0.001 vs baseline and placebo), with 84% of repaglinide-recipients achieving an HbA 1c of less than 7.5%, and 50% achieving an HbA 1c of less than 6.5%. In contrast, there was no signi®cant change in HbA 1c in patients randomised to placebo (7.6% and 7.4% at baseline and endpoint, respectively). Importantly, the repaglinide-associated improvement in HbA 1c occurred regardless of whether patients ate two, three or four meals (with preprandial dosing) per day as their most common meal pattern. Improved glycaemic control was also demonstrated in all repaglinide-treated subgroups when patients were strati®ed by body mass index.
Another study randomised 25 patients with Type 2 diabetes to receive prandial repaglinide for 20 days in either a ®xed three-mealaday regimen or a¯exible mealtime regimen, consisting of alternating days of two, three and four meals. 34 In this study, both regimens reduced mean fructosamine concentrations to normal levels (from 3.10 to 2.68 mgadl in the ®xed-meal group and from 3.37 to 2.85 mgadl in the mixedmeal regimen, both P`0.05), and there was no signi®cant between-group difference in the 24 h area under the curve (AUC) for serum glucose. A recently completed prospective investigation in a daily clinical setting involving nearly 6000 patients in Germany is discussed by Landgraf et al 27 in this publication. This has also con®rmed clinical ef®cacy when repaglinide is used empirically as a¯exible prandial glucose regulator. A two-pronged approach to Type 2 diabetes: regulation of prandial glucose and insulin sensitivity As discussed earlier, the progressive loss of the earlyphase prandial insulin response is often superimposed on a background of insulin resistance in Type 2 diabetes. An appealing strategy, therefore, for patients in poor control with oral monotherapy, or for those with a high degree of established insulin resistance, would be to combine prandial glucose regulation with the use of insulin sensitising agents. Indeed, it is particularly pertinent to combine a prandial glucose regulator with an insulin sensitiser of the thiazolidinedione group, given that the presence of suf®cient insulin is a prerequisite for ef®cacy with these sensitisers. 35 ± 37 The feasibility of this combination approach has been established in two studies of prandial repaglinide, one involving a thiazolidinedione and the other the biguanide, metformin.
A study involving 256 patients, currently treated with OHA monotherapy for Type 2 diabetes, compared repaglinide, troglitazone and the combination of these agents in a three-way parallel group design. 38 After a washout period to establish baseline characteristics, HbA 1c decreased over the 22-week study period from 8.8 to 8.0% in repaglinide-treated patients, from 8.5 to 8.1% in troglitazone-treated patients, and from 8.7 to 7.0% in the combination therapy group (Figure 3) . Repaglinide was signi®-cantly more effective than troglitazone in this respect (P`0.05), while combination therapy was signi®-cantly more effective than monotherapy (P`0.05). The incidence of symptomatic hypoglycaemia con®rmed by self-assessed blood glucose readings of`45 mgadl (2.5 mmolal) were 5%, 6% and 3% in the repaglinide, combination and troglitazone groups respectively, suggesting that combination therapy was not associated with a substantially increased risk of this adverse drug reaction. Despite the relative excess of hypoglycaemia in the repaglinide monotherapy group compared with the troglitazone monotherapy group, the drop-out rate was higher among the troglitazone-treated patients group (28% vs 11%), with ineffective therapy' given as the most common reason. Thus, this study con®rms the potential value of combining prandial glucose regulation with thiazolidinedione therapy.
The combination of repaglinide and metformin has also been assessed, in a three-month study of 83 patients with Type 2 diabetes no longer adequately controlled by metformin after a period of about 4 y. 39 In this study, the addition of repaglinide to metformin resulted in signi®cant improvements in glycaemic control: HbA 1c and fasting plasma glucose decreased, respectively, from 8.3 to 6.9% (P 0.0016) and from 10.22 mmolal (184 mgadl) to 8.04 mmolal (144.7 mgadl) (P 0.0003), and 59% of these patients achieved an HbA 1c of less than 7.1%. No severe hypoglycaemic events were reported in association with combination therapy despite the majority of patients receiving this therapy achieving optimal control. In patients for whom repaglinide was substituted for metformin there was no deterioration, nor improvement, in parameters of glycaemic control. Again, however, repaglinide was a better-tolerated therapy; 30% of metformin-treated patients experienced diarrhoea, compared with 7% of repaglinidetreated patients.
Conclusions
Type 2 diabetes is characterised by a progressive early derangement of the prandial insulin response, in a setting of pre-existing insulin resistance. Early phase insulin release is delayed and attenuated with the result that postprandial plasma glucose reaches supraphysiological concentrations and fails to return to normal basal levels. This model of diabetes indicates modulation of the prandial de®cit as part of a total approach to disease management. In clinical trials, the ®rst available oral prandial glucose regulator, repaglinide, has established itself as an antidiabetic agent that is highly effective when used in¯exible mealtime regimens. It incurs a low risk of severe hypoglycaemia compared with sulphonylureas, with which it has similar ef®cacy, and affords patients greater freedom in eating behaviours. In patients in whom insulin resistance has been identi®ed, or in whom glycaemic control with conventional monotherapies is suboptimal, the strategy of prandial glucose regulation with repaglinide can be combined with the use of an insulin sensitising agent to provide a synergistic effect that does not jeopardise tolerability. Repaglinide was signi®cantly more effective than troglitazone, while combination therapy was signi®cantly more effective than monotherapy (both cases, P`0.05). From reference 38.
